236 related articles for article (PubMed ID: 27166270)
1. Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.
de Miguel-Luken MJ; Chaves-Conde M; Quintana B; Menoyo A; Tirado I; de Miguel-Luken V; Pachón J; Chinchón D; Suarez V; Carnero A
Oncotarget; 2016 May; 7(22):31723-37. PubMed ID: 27166270
[TBL] [Abstract][Full Text] [Related]
2. MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.
de Miguel-Luken MJ; Chaves-Conde M; de Miguel-Luken V; Muñoz-Galván S; López-Guerra JL; Mateos JC; Pachón J; Chinchón D; Suarez V; Carnero A
Oncotarget; 2015 May; 6(14):12625-36. PubMed ID: 25788275
[TBL] [Abstract][Full Text] [Related]
3. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
5. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
6. Effect of daily fraction size on laryngoesophageal dysfunction after chemoradiation for squamous cell carcinomas of the larynx and hypopharynx.
Chen AM; Hsu S; Meshman J; Chin R; Beron P; Abemayor E; St John M
Head Neck; 2017 Jul; 39(7):1322-1326. PubMed ID: 28301066
[TBL] [Abstract][Full Text] [Related]
7. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J
Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
[TBL] [Abstract][Full Text] [Related]
9. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
11. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
Bar-Ad V; Wang ZX; Leiby B; Tuluc M
J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.
Fuller CD; Mohamed AS; Garden AS; Gunn GB; Mulcahy CF; Zafereo M; Phan J; Lai SY; Lewin JS; Hutcheson KA; Frank SJ; Beadle BM; Morrison WH; El-Naggar AK; Kocak-Uzel E; Ginsberg LE; Kies MS; Weber RS; Rosenthal DI
Head Neck; 2016 Dec; 38(12):1739-1751. PubMed ID: 27466789
[TBL] [Abstract][Full Text] [Related]
13. HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma.
Wang H; Zhang Z; Sun R; Lin H; Gong L; Fang M; Hu WH
J Voice; 2015 May; 29(3):356-62. PubMed ID: 25484261
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Ahn D; Sohn JH; Kim JH; Lee JE; Park SH; Kim JC
Ear Nose Throat J; 2016 Feb; 95(2):E34-42. PubMed ID: 26930342
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.
Birkeland AC; Beesley L; Bellile E; Rosko AJ; Hoesli R; Chinn SB; Shuman AG; Prince ME; Wolf GT; Bradford CR; Brenner JC; Spector ME
Head Neck; 2017 Dec; 39(12):2512-2518. PubMed ID: 28963806
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
19. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
Lavertu P; Adelstein DJ; Myles J; Secic M
Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
[TBL] [Abstract][Full Text] [Related]
20. Nuclear survivin expression correlates with endoglin-assessed microvascularisation in laryngeal carcinoma.
Marioni G; Ottaviano G; Marchese-Ragona R; Fasanaro E; Tealdo G; Zanotti C; Randon B; Giacomelli L; Stellini E; Blandamura S
J Clin Pathol; 2017 Dec; 70(12):1033-1037. PubMed ID: 28446541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
